Entrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar Sells 1,718 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar sold 1,718 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $6.85, for a total value of $11,768.30. Following the completion of the transaction, the director owned 2,846,592 shares in the company, valued at approximately $19,499,155.20. This trade represents a 0.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Kush Parmar also recently made the following trade(s):

• On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.93, for a total value of $795,259.08.

Entrada Therapeutics Stock Performance

TRDA stock opened at $7.26 on Tuesday. Entrada Therapeutics, Inc. has a fifty-two week low of $4.93 and a fifty-two week high of $16.45. The business’s 50-day moving average is $6.84 and its two-hundred day moving average is $9.82. The company has a market cap of $281.83 million, a price-to-earnings ratio of -1.82 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.11. The business had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $2.92 million. Entrada Therapeutics had a negative return on equity of 51.22% and a negative net margin of 2,895.05%. Equities analysts predict that Entrada Therapeutics, Inc. will post -4.12 earnings per share for the current year.

Key Headlines Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Institutional ownership remains substantial at 86.39%, with Baker Bros. Advisors, Wellington Management, Millennium Management, Geode Capital and State Street among funds that recently increased their positions. Analysts’ consensus price target of $17.50 also remains well above the stock’s recent trading level, although the consensus rating is “Hold.”
• Neutral Sentiment: Entrada’s latest quarterly results beat expectations on adjusted earnings, reporting a loss of $0.95 per share versus the projected $1.06 loss. However, revenue of $0.88 million was well below the $2.92 million estimate, underscoring the company’s early-stage, clinical-biotechnology profile and ongoing losses.
• Negative Sentiment: Director Kush Parmar and major shareholder Ventures L.P. 5AM each disclosed the sale of 114,756 shares at an average price of $6.93, worth approximately $795,259. The disclosures appear to represent the same transaction reported through related filings, rather than two separate sales. The sale reduced the holder’s position by 3.87%, leaving approximately 2.85 million shares.
• Negative Sentiment: The same insiders also reported a separate sale of 1,718 shares at an average price of $6.85, valued at about $11,768. This reduced ownership by only 0.06%, making it a relatively minor transaction. Entrada Therapeutics Director Kush Parmar Sells Shares

Analyst Ratings Changes

TRDA has been the subject of several recent research reports. Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. Guggenheim dropped their price target on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Roth Capital set a $10.00 price target on shares of Entrada Therapeutics in a research note on Friday, May 8th. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Finally, Oppenheimer upped their price objective on Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a research note on Monday, April 6th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $17.50.

Hedge Funds Weigh In On Entrada Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in shares of Entrada Therapeutics by 7.2% in the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after purchasing an additional 42,479 shares in the last quarter. Rhumbline Advisers boosted its holdings in Entrada Therapeutics by 8.3% in the 2nd quarter. Rhumbline Advisers now owns 39,095 shares of the company’s stock worth $263,000 after buying an additional 2,982 shares during the period. American Century Companies Inc. boosted its holdings in Entrada Therapeutics by 10.8% in the 2nd quarter. American Century Companies Inc. now owns 75,094 shares of the company’s stock worth $505,000 after buying an additional 7,301 shares during the period. Prudential Financial Inc. increased its stake in Entrada Therapeutics by 23.4% in the 2nd quarter. Prudential Financial Inc. now owns 28,340 shares of the company’s stock worth $190,000 after buying an additional 5,370 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Entrada Therapeutics by 34.2% in the 2nd quarter. Invesco Ltd. now owns 22,393 shares of the company’s stock worth $150,000 after buying an additional 5,702 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.